Macitentan in inoperAble or persistent/reCurrent chronIc ThromboEmbolic Pulmonary Hypertension (MACiTEPH)

Purpose of Study:

To evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).

Study Dates:
July 7, 2020 - May 14, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Actelion Pharmaceuticals Ltd*

Sponsors:

Janssen Pharmaceutical Company of Johnson & Johnson

ClinicalTrails.gov Identifier:
NCT04271475

Register for Trial